Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human SPARC(SPARC) ELISA kit

Human SPARC(SPARC) ELISA kit

  • 中文名稱：
    人SPARC(SPARC)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-EL022486HU
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    This Human SPARC ELISA Kit was designed for the quantitative measurement of Human SPARC protein in serum, plasma, tissue homogenates, urine. It is a Sandwich ELISA kit, its detection range is 62.5 ng/mL-4000 ng/mL and the sensitivity is 15.6 ng/mL.

  • 別名：
    AA517111 ELISA Kit; Basement membrane protein 40 ELISA Kit; Basement-membrane protein 40 ELISA Kit; BM 40 ELISA Kit; BM-40 ELISA Kit; BM40 ELISA Kit; Cysteine rich protein ELISA Kit; hm:zeh0062 ELISA Kit; MGC128090 ELISA Kit; OI17 ELISA Kit; ON ELISA Kit; Osteonectin ELISA Kit; Secreted acidic cystein rich glycoprotein ELISA Kit; Secreted protein acidic and cysteine rich ELISA Kit; Secreted protein acidic and rich in cysteine ELISA Kit; Secreted protein acidic cysteine rich (osteonectin) ELISA Kit; Secreted protein acidic cysteine rich ELISA Kit; SPARC ELISA Kit; SPRC ELISA Kit; SPRC_HUMAN ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates, urine
  • 檢測范圍：
    62.5 ng/mL-4000 ng/mL
  • 靈敏度：
    15.6 ng/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human SPARC in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)
    1:1 Average % 84
    Range % 81-89
    1:2 Average % 93
    Range % 89-97
    1:4 Average % 98
    Range % 94-102
    1:8 Average % 100
    Range % 95-105
  • 回收率：
    The recovery of human SPARC spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range
    Serum (n=5) 90 87-93
    EDTA plasma (n=4) 101 97-104
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected
    4000 2.120 2.301 2.211 2.049
    2000 1.667 1.642 1.655 1.493
    1000 1.173 1.163 1.168 1.006
    500 0.759 0.787 0.773 0.611
    250 0.453 0.469 0.461 0.299
    125 0.307 0.301 0.304 0.142
    62.5 0.254 0.259 0.257 0.095
    0 0.163 0.160 0.162 　
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點詳情

  • 功能：
    Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity.
  • 基因功能參考文獻(xiàn)：
    1. Hepatic SPARC expression is associated with liver injury and fibrogenic processes in non-alcoholic fatty liver disease. PMID: 29335425
    2. Plasma samples from lung cancer patients and healthy heavy-smokers controls were tested for levels of COL11A1 and COL10A1 (n = 57 each) and SPARC (n = 90 each). Higher plasma levels of COL10A1 were detected in patients (p PMID: 30227835
    3. The authors have confirmed the presence of SPARC expression in melanoma, Kaposi sarcomas (KS), leiomyosarcomas (LMS) and angiosarcomas (AS) and also detected it for the first time in atypical fibroxanthomas (AFX). PMID: 29660567
    4. Results revealed that hypermethylation of the SPARC promoter was the primary mechanism of SPARC downregulation in prostate cancer. SPARC expression was frequently lost during the promoter hypermethylation but could be restored by 5-Aza-Cdr. PMID: 29207175
    5. Stromal SPARC expression was a useful biomarker for predicting prognosis in patients with resected pancreatic ductal adenocarcinoma. PMID: 29295776
    6. SPARC is closely related to the development of breast cancer and can be used as a tumor marker for breast cancer recurrence. PMID: 29237913
    7. SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. PMID: 29075785
    8. SPARC may be involved in gastric cancer metastasis by effecting on tumor microenvironment PMID: 29077165
    9. SPARC treatment enhances the epithelial mesenchymal transition signaling pathway via activation of AKT, and exogenous SPARC and tumor expressing SPARC might be associated with tumor progression in head and neck cancers. PMID: 28718842
    10. The epicardial adipose tissue expresses the mRNA of osteopontin, osteoprotegerin, and osteonectin genes that have been implicated in the calcification process; such expression is statistically associated with some components of HDL subclasses in coronary artery disease patients. PMID: 28821297
    11. detection of SPARC mRNA and protein expression levels may facilitate early diagnosis and prognosis assessment of esophageal squamous cell carcinoma. PMID: 28713937
    12. SPARC rs17718347 and rs2347128 single nucleotide polymorphisms are associated with progression-free survival in locally advanced and metastatic pancreatic cancer patients. PMID: 28687963
    13. results demonstrated that loss of miR-211 expression and thus uncontrolled SPARC overexpression might drive progression of hepatocellular carcinoma (HCC), which may provide a novel therapeutic strategy for the treatment of HCC. PMID: 27230656
    14. Data suggest that plasma SPARC levels may be biomarker for vascular complications among Chinese type 2 diabetic patients; patients in lowest SPARC tertile have increased odds of aortic stiffness but reduced odds of peripheral arterial disease. PMID: 28479157
    15. The profiled circulating tumour cells also expressed elevated levels of stem cell markers, and the extracellular matrix protein, SPARC. The expression of SPARC might correspond to an epithelial-mesenchymal transition in pancreatic circulating tumour cells PMID: 28569190
    16. Data suggest that both osteonectin and FGF21 levels in serum are associated with early nephropathy in type 2 diabetes, albeit with different patterns; persistent hyperglycemia may inhibit bone formation leading to osteoporosis. (FGF21 = fibroblast growth factor 21) PMID: 27916484
    17. These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer. PMID: 27421134
    18. High expression of SPARC is related to worse prognosis in rectal cancer patients. PMID: 28009327
    19. Tumors with stroma-derived SPARC displayed suppressed growth, inhibited angiogenesis and increased lipid accumulation. Based on the described chaperone function of SPARC, authors hypothesized that SPARC binds albumin complexed with fatty acids and transports them to tumors. PMID: 27776337
    20. Weekly NAB-paclitaxel might be effective for heavily pretreated non-small-cell lung cancer patients. SPARC expression in tumor stroma cells might be a potential negative predictor of NAB-paclitaxel. PMID: 28304139
    21. SPARC-associated signaling pathways are associated with lymphangiogenesis and lymph node metastases of hypopharyngeal cancer. PMID: 29374693
    22. Stromal SPARC expression correlated with the prognosis of patients with resectable biliary carcinoma, and its significance was enhanced in patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 28342122
    23. Studies revealed that SPARC plays a critical role in regulating bone remodeling and maintaining bone mass and quality. The mechanisms by which SPARC influences bone formation, maintenance, and repair might occur through multiple pathways that include the regulation of procollagen processing and assembly in the bone matrix, crosslinking, mineralization, and/or osteoblast/osteoclast differentiation and activity. [review] PMID: 26851678
    24. This study indicates that germline PTCH1 heterozygous mutations play a major role in bone metabolism in patients with NBCCS, in particular in those with PTCH1 protein truncation mutations. SPARC may represent an important downstream modulator of PTCH1 mediation of bone metabolism. PMID: 26890308
    25. The SPARC drives pathological responses in non-small cell lung cancer and idiopathic pulmonary fibrosis by promoting microvascular remodelling and excessive deposition of ECM proteins. PMID: 27759879
    26. proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin expression was significantly increased in the intratumoral stroma of pancreatic ductal adenocarcinomas compared to paired non-neoplastic pancreata PMID: 29025374
    27. The mRNA and protein levels of SPARC were 5.78-fold higher in cancer tissues compared with the case-matched normal epithelium. High expression levels of SPARC in esophageal squamous cell carcinoma parenchyma were related to lymph node metastasis and poor prognosis (p = 0.049 and p = 0.04). PMID: 28818666
    28. SPARC can serve a dual function role as both predictor for prognosis and potentially biomarker for lymph node metastasis in resected pancreatic cancer patients. PMID: 28119265
    29. SPARC appears to be an important modulator of the actin cytoskeleton, implicating maintenance of muscular function PMID: 27908613
    30. that SPARC-mediated degradation of the extracellular matrix, and its possible association with MMPs, might contribute to progression of phyllodes tumors PMID: 27909812
    31. WIN-dependent increase in the level of SPARC plays a critical role in sensitizing osteosarcoma cells to TRAIL action PMID: 26698404
    32. high SPARC-expression was a significant predictor of poor OS in HPV-negative OPSCC patients using Kaplan-Meier analysis and the log-rank test PMID: 26523779
    33. We identified five new biomarkers: GDF15, osteonectin, TRAP5, TWEAK, and YKL40 as being promising markers for monitoring bone metastases. PMID: 27069189
    34. SPARC levels were not associated with efficacy in patients with MPC. This exploratory analysis does not support making treatment decisions regarding nab-paclitaxel plus gemcitabine or gemcitabine alone in MPC based on SPARC expression. PMID: 26169969
    35. CD90 is upregulated in gastric cancer and inhibits gastric cancer cell apoptosis by modulating the expression level of SPARC protein. PMID: 26329007
    36. SPARC might be an unfavorable indicator in patients with pancreatic cancer, especially in the stroma.[Review] PMID: 26731428
    37. tracheal aspirate SPARC levels predicted development of bronchopulmonary dysplasia or death. PMID: 26656750
    38. SPARC is associated with carcinogenesis of oral squamous epithelium. PMID: 25311631
    39. Studies indicate that SPARC (secreted protein acidic and rich in cysteine) gene is involved in the development and progression of pancreatic ductal adenocarcinoma (PDAC). PMID: 26335014
    40. MLKL upregulation in SPARC overexpressed cells treated with Ara-C, indicates necrosis as a possible cell death process for the SKM-1 cells under these stringent conditions. PMID: 26165695
    41. up-regulation of SPARC by oxLDL is independent of Runx2, and it may be mediated by other transcription factors PMID: 26025968
    42. Tumor-produced SPARC and VCAM1 are regulators of cancer extravasation. PMID: 25925867
    43. miR-29a and miR-29b enhance cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. PMID: 25786138
    44. SNP1599 differentially regulates osteonectin expression and contributes to variability in bone mass, by a mechanism that may involve differential targeting by miR-433 PMID: 25262637
    45. Reduced expression of SPARC in colorectal cancer tissue is associated with poor prognosis and aggressive clinicopathological features. PMID: 26044224
    46. Three functional SPARC SNPs are associated with an increased risk of coal workers' pneumoconiosis in a Chinese population. PMID: 25126876
    47. reduced expression in the bone marrow biopsy specimen in patients with aplastic anemia PMID: 25032754
    48. SPARC promoter methylation as an important factor in the tumorigenesis of gastric carcinomas. PMID: 25516351
    49. SCD5 impairs SPARC and cathepsin B secretion in human melanoma cells and intracellular pH acidification. PMID: 25802234
    50. High SPARC expression of the primary tumor is associated with a higher chance of achieving a pathological complete remission after TAC or TAC-NX chemotherapy. PMID: 25355716

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Osteogenesis imperfecta 17 (OI17)
  • 亞細(xì)胞定位：
    Secreted, extracellular space, extracellular matrix, basement membrane. Note=In or around the basement membrane.
  • 蛋白家族：
    SPARC family
  • 數(shù)據(jù)庫鏈接：

    HGNC: 11219

    OMIM: 182120

    KEGG: hsa:6678

    STRING: 9606.ENSP00000231061

    UniGene: Hs.111779